Last Updated : July 27, 2023
Details
Project Line:
Reimbursement Review
Project Sub Line:
Pharmaceutical Review Update
Canada's Drug Agency Program Updates
- Drug Reimbursement Reviews for COVID-19 Drugs
Canada's Drug Agency has received requests from participating public drug plans about reimbursement recommendations for existing and future COVID-19 drugs. The national procurement process for COVID-19 drugs was initially established to support Health Canada’s emergency authorizations and access through the Public Health Agency of Canada. However, it is assumed that access will eventually transition from a centralized process to the provinces and territories. In anticipation of this transition, and to support ongoing access to these products, sponsors can now submit drugs for COVID-19 to the Canada's Drug Agency Drug Reimbursement Review program.
For more information on the drug reimbursement review process, please refer to the Procedures for Canada's Drug Agency Drug Reimbursement Reviews or submit questions to [email protected].
Last Updated : July 27, 2023
